Our data support previous evidence demonstrating that in ER+ breast cancer, exogenous Chol may be relevant to the tumor microenvironment and its metabolite, 27-hydroxyChol, may modulate ER activity [38]. The gene discussed is ESR1; the disease is neoplasm.